GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » PB Ratio

Artelo Biosciences (Artelo Biosciences) PB Ratio : 0.49 (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-06), Artelo Biosciences's share price is $1.4399. Artelo Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was $2.96. Hence, Artelo Biosciences's PB Ratio of today is 0.49.

The historical rank and industry rank for Artelo Biosciences's PB Ratio or its related term are showing as below:

ARTL' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 7.54
Current: 0.49

During the past 10 years, Artelo Biosciences's highest PB Ratio was 7.54. The lowest was 0.00. And the median was 0.00.

ARTL's PB Ratio is ranked better than
93.82% of 1310 companies
in the Biotechnology industry
Industry Median: 2.535 vs ARTL: 0.49

During the past 12 months, Artelo Biosciences's average Book Value Per Share Growth Rate was -52.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.90% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Artelo Biosciences was 115.50% per year. The lowest was -34.70% per year. And the median was -2.80% per year.

Back to Basics: PB Ratio


Artelo Biosciences PB Ratio Historical Data

The historical data trend for Artelo Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences PB Ratio Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.24 1.86 0.43 0.38

Artelo Biosciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.35 0.32 0.38 0.50

Competitive Comparison of Artelo Biosciences's PB Ratio

For the Biotechnology subindustry, Artelo Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's PB Ratio falls into.



Artelo Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Artelo Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=1.4399/2.955
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Artelo Biosciences  (NAS:ARTL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Artelo Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Executives
Gregory D. Gorgas director, officer: See Remarks 888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes director 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck director C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele director
David J Moss 10 percent owner C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly director C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney director C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien 10 percent owner C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus